US2020140832A1PendingUtilityA1

Anti-inflammatory peptides and composition comprising the same

Assignee: KIM SANG JAEPriority: Jul 20, 2012Filed: Jan 17, 2020Published: May 7, 2020
Est. expiryJul 20, 2032(~6 yrs left)· nominal 20-yr term from priority
A61K 38/45A61P 11/00A23L 33/18A61P 9/00A61P 25/00A61P 31/00A61P 1/00A61P 29/00A61P 37/00C12N 9/1276C12Y 207/07049A61P 17/00A61P 19/00A61P 15/00C07K 14/435A61P 13/00A61P 35/00A61K 38/00A61P 43/00C07K 14/47A23V 2002/00Y02A50/411Y02A50/385Y02A50/422Y02A50/30
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO:1 to SEQ ID NO:161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO:1 to SEQ ID NO:161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.

Claims

exact text as granted — not AI-modified
1 - 21 . (canceled) 
     
     
         22 . A method of treating or preventing inflammatory disease in a patient, comprising administering to the patient an isolated peptide having anti-inflammatory activity, wherein the peptide is 10 amino acids in length and has the amino acid sequence of SEQ ID NO: 4. 
     
     
         23 . The method according to  claim 22 , wherein the inflammatory disease is selected from the group consisting of general or localized inflammatory disease; gastro-intestinal related diseases; dermal related diseases; vascular related disease; respiratory diseases; bone, joint, muscle, and connective tissue related diseases; urogenital disorders; central or peripheral nervous system related diseases; virus; and autoimmune diseases. 
     
     
         24 . The method according to  claim 22 , wherein the peptide originates from human telomerase. 
     
     
         25 . The method according to  claim 22 , wherein the peptide increases high mobility group protein box 1 (HMGB1) expression in a nucleus of a cell. 
     
     
         26 . The method according to  claim 22 , wherein the peptide reduces the expression level of TNF-α. 
     
     
         27 . A method of treating or preventing skin inflammation comprising administering an isolated peptide having anti-inflammatory activity, wherein the peptide is 10 amino acids in length and has the amino acid sequence of SEQ ID NO: 4. 
     
     
         28 . The method according to  claim 27 , wherein the peptide originates from human telomerase. 
     
     
         29 . The method according to  claim 27 , wherein the peptide increases high mobility group protein box 1 (HMGB1) expression in a nucleus of a cell. 
     
     
         30 . The method according to  claim 27 , wherein the peptide reduces the expression level of TNF-α.

Join the waitlist — get patent alerts

Track US2020140832A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.